| Message: | Product Name: Letrozole
Alias: Femara,Lelrozol,TROZET,Letroz,Lelroz,Letrozolex
CAS: 112809-51-5
Molecular Formula: C17H11N5
Molecular Weight: 285.3
Purity: 98%
Grade: Pharmaceutical Grade
Appearance: White Crystalline Powder
Letrozole Profile
Letrozoles are non suicidal Aromatase Inhibitors, belonging to the third generation of aromatase inhibitors. They are administered orally and hold the approval of the Food and Drug Administration of the United States (FDA) for use in treating two particular kinds of breast cancer. One is the case when hormone receptor positive breast cancer develops locally or is contracted through metastatis. The other is a similar case but when the cancer is of the estrogen receptor unknown category.
The estrogen receptor unknown category refers to those breast cancer conditions where the role of estrogens can not be determined with certainty. In these cases, it is impossible to predict if estrogen caused the cancer in the first place or if it would complicate and worsen the cancer further. Letrozoles are used in the treatment of such cancer conditions in post menopausal women. It is however rare that Letrozole be required for treating the post menopausal estrogen receptor unknown cancer, first-line. In most cases, it is used only after the usual first-line treatments using Selective Estrogen Receptor Modulator drugs like the Nolvadex have failed to show any positive effects.
|
my account
